Company intelligence / Profile preview

Seger Surgical Solutions

Misgav, Northern District, Israel

Ownership: Private
Development stage: Other

Overview

Seger Surgical Solutions is developing LAP IA/LAP IA 60, a laparoscopic bowel closure stapling device that enables fast, secure, fully intracorporeal anastomosis; the company has completed animal studies and is preparing for human trials and FDA clearance in collaboration with Waston Medical, but no human clinical outcomes data have been reported yet.

Therapeutic areas: Gastroenterology
Modalities: DeviceNon-pharmacological therapy
Industry: Surgical Medical Devices

Partnerships

Waston Medical (collaboration to validate device for human trials and FDA clearance)The Trendlines Group (portfolio company / investor and incubator relationship)

Beyond the preview

Go deeper on Seger Surgical Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seger Surgical Solutions.

Explore the full profile